Skip to content
Close-up of glass vials moving through an automated pharmaceutical filling line with stainless steel machinery.

Large-scale aseptic fill & finish

High-speed filling: – where efficiency and process safety must go hand in hand

Learn more

Monday morning, day four of a large campaign. Since Friday, nested syringes have been flowing into the isolator and the filling needles have been dosing in a steady rhythm. Then a routine glove test flags a pinhole. Within minutes, one question decides the rest of the week: stop, investigate, and re-decontaminate – or can production safely continue?

Situations like this show how much is at stake in large-scale filling. Demand for injectables, from GLP-1 therapies to biosimilars and vaccines, is growing faster than new lines can be built. The fill-finish market is expected to grow by nearly USD 10 billion between 2026 and 2031, and demand is likely to outpace capacity for years.

Most of these products cannot be terminally sterilized, so every unit depends on the aseptic process – and every hour a high-speed line stands still means doses that do not reach patients.

At the same time, the bar keeps rising. The revised Annex 1 places barrier technology and minimal intervention at the center of sterile manufacturing, and lines built only a decade ago may no longer meet these expectations.

This page looks at the demands faced by large-scale filling today – from the areas that have to work together on a line to the key challenges, and the approaches that address them.

Overview

What a working filling line needs

A filling machine alone does not make a filling line. Behind every reliable high-speed line, many different disciplines and areas of knowledge work hand in hand – and only together do they keep a line aseptic, compliant, and available.

Hotspot image
  • Barrier and containment

    The isolator separates operators from the open product and forms the core of Annex 1 compliance. For potent products, it also has to protect operators from exposure.

  • Glove management

    Gloves are the most frequent contact between operator and critical zone. Their selection, integrity testing and exchange need a defined concept.

  • Special requirements for bulk vial lines

    Lines for bulk vials add washing and depyrogenation before filling. Products that need freeze-drying also require a lyophilizer with aseptic loading and unloading.

  • Transfer systems

    Every item entering Grade A is a potential contamination source. Packaging materials, tools and liquids each need a suitable transfer concept that works without stopping the line.

  • Bio-decontamination

    H₂O₂ cycles create aseptic conditions inside the barrier. They have to be fast to keep the line available – and tailored to the product, so that sensitive biologics remain unaffected.

  • Filling and closing

    The filling machine doses the product into ready-to-use containers and closes them. Precise dosing and in-process control decide yield.

  • Environmental monitoring

    Continuous monitoring of particles and microorganisms shows whether the critical zone stays under control. It provides the data behind the contamination control strategy.

  • Automation and data

    The control system runs and records every step of the process. Automated inspection and an electronic batch record keep pace with high speeds and support faster release.

  • Lifecycle

    A filling line runs for decades, while guidelines, products and control technology keep changing. Keeping it in a qualified state means planning early for spare parts, outdated automation, requalification after changes and upgrades to new formats.

At a glance

Key challenges in large-scale filling

  • Annex 1 compliance

    Barrier technology and a living CCS are now expected – also for older lines.

  • Material transfer

    Every item entering Grade A during a campaign is a potential contamination source.

  • Glove integrity

    A single undetected glove breach can call an entire batch into question.

  • H₂O₂-sensitive products

    The decontamination concept must be tailored so that residues do not affect the product.

  • Potent products

    Highly potent drugs require protection for operators as well as the product.

  • Constant availability

    Every hour a high-speed line stands still means lost supply.

  • Shifting formats

    Syringes and cartridges are gaining share relative to vials.

Addressing the challenges

Creating robust processes while protecting product and people

  • Operator monitoring integra filling line via touchscreen in cleanroom isolator environment.

    Annex 1 compliance: Barrier and proof

    Isolators are increasingly the expected standard, as they separate operators from the open product and minimize interventions. Compliance also has to be demonstrated: decontamination success must be verified across the life cycle.

    → Read more: Annex 1 and its impact on isolator design

  • Clean integra isolator interior with glove ports for aseptic operations.

    Material transfer and glove integrity: Interfaces under control

    Material transfers and gloves are where the barrier is most often challenged. Transfer concepts that work during production and a defined glove management concept keep Grade A closed.

    → Read more: Comparison of aseptic transfer systems and their applications

  • Tupfertest am Isolator in einem weissen Quadrat

    Potent products: Containment, verified by measurement

    For highly potent drugs, the barrier also has to protect operators, and its performance should be proven rather than assumed. Standardized surrogate tests such as SMEPAC show whether the required exposure limits are met.

    → Read more: SMEPAC Containment Test

Addressing the challenges

Keeping the line running

  • Availability and sensitive products: Fast, gentle decontamination

    Decontamination is often the longest non-productive phase between campaigns, and its concept has to match the product. Understanding how vaporized H₂O₂ behaves allows short, robust cycles, while materials chosen for their H₂O₂ interaction ensure that sensitive biologics remain unaffected.

  • Formats and lifecycle: Flexible lines, planned for decades

    A prefilled syringe line is not simply a vial line with different parts, and portfolios change over a line’s lifetime. Multipurpose designs with quick changeover and a life cycle plan for spare parts, automation updates, and requalification keep the line productive and compliant.

Technician in a full blue cleanroom suit working at a stainless steel isolator line in a sterile pharmaceutical production facility.

Expertise for large-scale filling

Back to Monday morning: whether the line can keep running after the glove alarm depends on many disciplines at once – glove testing and monitoring data, the decontamination cycle and its residues, the transfer concept and the Contamination Control Strategy behind it all. A filling line is only as reliable as the way these pieces fit together.

This is where SKAN’s experience comes in. With more than 1,000 isolators installed, SKAN designs every line around the customer’s process and site rather than a fixed platform. Filling and lyophilization equipment from different suppliers can be integrated, existing buildings can be used, and virtual mock-ups let operators test interventions before manufacturing starts.

Every interface to Grade A is covered: transfer systems aligned with Annex 1, glove integrity testing, monitoring concepts matched to the Contamination Control Strategy and low-concentration H₂O₂ decontamination that shortens cycles and reduces residues. Containment up to OEB 6 protects operators, and in-house applied science provides the data on materials and residues.

SKAN lines are built to run for decades. Requalification support and retrofits keep them compliant as guidelines and products change, backed by active work in ISPE, PDA, and ISO groups that helps translate new requirements into inspection-ready designs.

Let's talk about your filling line

Planning new capacity or upgrading an existing line? Let’s discuss your products, formats and site.

Back to top